SCORAD
Calculate the SCORAD index for atopic dermatitis severity assessment. Free online medical calculator with extent, intensity, and subjective symptom scoring for eczema evaluation.
A — Extent (% of affected body surface area)
B — Clinical Signs Intensity
C — Subjective Symptoms (last 3 days)
About This Calculator
About the SCORAD Index
The SCORAD (SCORing Atopic Dermatitis) index is a validated, widely used clinical tool for assessing the severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis, the SCORAD index provides a comprehensive evaluation by combining objective clinical assessment with patient-reported subjective symptoms. It is one of the most extensively validated and frequently used outcome measures in atopic dermatitis clinical research and practice, with over two decades of use in clinical trials and routine dermatology care worldwide.
The SCORAD index evaluates three components. Component A assesses the extent of affected body surface area using the rule of nines across six body regions: head and neck (9%), upper extremities (18%), anterior trunk (18%), back (18%), lower extremities (36%), and genitals (1%). The clinician estimates the percentage of each region affected by atopic dermatitis lesions. Component B evaluates the intensity of six clinical signs — erythema, edema/papulation, oozing/crusting, excoriation, lichenification, and dryness — each scored from 0 (none) to 3 (severe). Component C captures subjective symptoms reported by the patient: pruritus (itching) intensity and sleep loss over the preceding three days, each scored on a visual analog scale from 0 to 10. The total SCORAD score is calculated as A/5 + 7×B/2 + C, producing a score range from 0 to 103.
SCORAD scores are classified into three severity categories: mild (0—25), moderate (26—50), and severe (51—103). This classification guides treatment decisions in clinical practice — mild cases may be managed with emollients, topical corticosteroids, and trigger avoidance; moderate cases typically require more potent topical treatments, phototherapy, or systemic therapy; severe cases often necessitate advanced therapies including biologic agents such as dupilumab (FDA and EMA approved for moderate-to-severe atopic dermatitis), Janus kinase (JAK) inhibitors, or systemic immunosuppressants under specialist supervision. The SCORAD index demonstrates excellent inter-rater reliability and correlates well with other severity measures including the EASI score, Investigator's Global Assessment (IGA), and quality of life instruments.
Regional Notes
India: Atopic dermatitis affects an estimated 5—10% of children and 1—3% of adults in India. The Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) recommends SCORAD for severity assessment in both clinical practice and research settings. In India, treatment approaches must consider tropical climate factors, access to dermatology services, and cost considerations for biologic therapies. Emollient therapy and trigger avoidance remain first-line recommendations across all regions.
US: The American Academy of Dermatology (AAD) guidelines recognize the SCORAD index as a validated severity assessment tool for atopic dermatitis. In the US, the SCORAD is commonly used alongside the EASI score in clinical trials and for determining eligibility for biologic therapy. The FDA has accepted SCORAD as a primary or secondary endpoint in atopic dermatitis clinical trials. Insurance coverage for advanced therapies often requires documented moderate-to-severe disease using validated scoring tools like SCORAD.
UK: NICE guidelines for atopic dermatitis reference the SCORAD index in the context of assessing disease severity and treatment pathways. The British Association of Dermatologists (BAD) recommends SCORAD for clinical assessment. In the NHS, the SCORAD is used alongside the Patient-Oriented Eczema Measure (POEM) and Dermatology Life Quality Index (DLQI) to guide treatment decisions and monitor response to therapy, including eligibility for dupilumab and other biologic therapies.
Frequently Asked Questions
What is the SCORAD index?
The SCORAD (SCORing Atopic Dermatitis) index is a validated clinical tool for assessing the severity of atopic dermatitis (eczema). It evaluates three components: A — extent of affected body surface area using the rule of nines (0—100%), B — intensity of six clinical signs including erythema, edema, oozing, excoriation, lichenification, and dryness (each scored 0—3), and C — subjective symptoms of pruritus (itching) and sleep loss (each 0—10). The total SCORAD score ranges from 0 to 103, with higher scores indicating more severe disease.
How is the SCORAD score calculated?
The SCORAD index is calculated using the formula: SCORAD = A/5 + 7×B/2 + C, where A is the total percentage of body surface area affected by atopic dermatitis (0—100), B is the sum of six clinical sign intensity scores (each 0—3, total 0—18), and C is the sum of pruritus and sleep loss scores (each 0—10, total 0—20). Component A divides the body into six regions using rule of nines factors: head and neck (9%), upper extremities (18%), anterior trunk (18%), back (18%), lower extremities (36%), and genitals (1%).
What is a normal SCORAD score?
A SCORAD score of 0 indicates no visible signs of atopic dermatitis. Scores from 0 to 25 are classified as mild disease, 26 to 50 as moderate disease, and 51 to 103 as severe disease. The higher the score, the more extensive and intense the atopic dermatitis symptoms. In clinical practice, disease severity guides treatment decisions — mild cases may be managed with emollients and topical corticosteroids, while moderate to severe cases may require phototherapy, systemic immunosuppressants, or biologic therapy such as dupilumab.
How is SCORAD different from EASI?
SCORAD (SCORing Atopic Dermatitis) and EASI (Eczema Area and Severity Index) are both validated tools for assessing atopic dermatitis severity. The key difference is that SCORAD includes a subjective component (pruritus and sleep loss reported by the patient) while EASI evaluates only objective clinical signs. SCORAD uses the rule of nines for extent calculation across six body regions and assesses six clinical signs, producing a score from 0 to 103. EASI evaluates four body regions with four clinical signs on a scale of 0 to 72. Both are widely used in clinical trials and practice.
Who can use the SCORAD calculator?
The SCORAD calculator is designed for dermatologists, general practitioners, pediatricians, allergists, and other healthcare professionals managing patients with atopic dermatitis. It can also be used by researchers in clinical trials evaluating treatments for eczema. Patients and caregivers may use it for educational purposes to understand disease severity, but should always consult a healthcare professional for clinical assessment and treatment decisions. The SCORAD index is validated for use in both adults and children.
Can the SCORAD index be used for children?
Yes, the SCORAD index is validated for use in children as young as infants. Atopic dermatitis affects approximately 10—20% of children worldwide, with onset often occurring in the first year of life. For children, the rule of nines body surface area estimation is adjusted — in infants, the head and neck proportion is larger (18%) and lower limbs proportion is smaller (27%). The clinical sign intensity assessment and subjective symptom scoring (pruritus and sleep loss) remain the same as for adults, though subjective symptoms may need to be reported by parents or caregivers for very young children.
What is the maximum SCORAD score?
The maximum SCORAD score is 103. This represents the most severe form of atopic dermatitis with 100% body surface area affected (A = 100, giving A/5 = 20), maximum intensity of all six clinical signs at the most severe level (B = 18, giving 7×18/2 = 63), and maximum subjective symptoms (C = 20 from pruritus 10 + sleep loss 10). In clinical practice, scores above 50 are classified as severe disease and typically warrant aggressive treatment including systemic therapy or biologics under specialist care.